Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma

Genes Chromosomes and Cancer

Volumn 53, Issue 7, 2014, Pages 589-605

  Riehmer, Vera ^a   Gietzelt, Jens ^b   Beyer, Ulrike ^a   Hentschel, Bettina ^b   Westphal, Manfred ^c   Schackert, Gabriele ^d   Sabel, Michael C ^e   Radlwimmer, Bernhard ^f   Pietsch, Torsten ^g   Reifenberger, Guido ^e   Weller, Michael ^h   Weber, Ruthild G ^a   Loeffler, Markus ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; BIOINFORMATICS; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CLONAL EVOLUTION; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DOSAGE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; PRIMARY TUMOR; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR RECURRENCE; BRAIN TUMOR; COPY NUMBER VARIATION; GENETICS; METABOLISM; PHYSIOLOGY; PROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; TRANSCRIPTOME;

EID: 84899967549     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22169     Document Type: Article

References (102)

1. Arai M, Kondoh N, Imazeki N, Hada A, Hatsuse K, Matsubara O, Yamamoto M. 2009. The knockdown of endogenous replication factor C4 decreases the growth and enhances the chemosensitivity of hepatocellular carcinoma cells. Liver Int 29:55-62.
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. 2008. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602.
3. Barbieri F, Pattarozzi A, Gatti M, Aiello C, Quintero A, Lunardi G, Bajetto A, Ferrari A, Culler MD, Florio T. 2009. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab 297:E1078-E1088.
4. Bau DT, Tsai CW, Wu CN. 2011. Role of the XRCC5/XRCC6 dimer in carcinogenesis and pharmacogenomics. Pharmacogenomics 12:515-534.
5. Berendsen S, Broekman M, Seute T, Snijders T, van Es C, de Vos F, Regli L, Robe P. 2012. Valproic acid for the treatment of malignant gliomas: Review of the preclinical rationale and published clinical results. Expert Opin Investig Drugs 21:1391-1415.
6. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR. 2007. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci USA 104:20007-20012.
7. Bertomeu T, Zvereff V, Ibrahim A, Zehntner SP, Aliaga A, Rosa-Neto P, Bedell BJ, Falardeau P, Gourdeau H. 2010. TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation. Biochem Pharmacol 80:1572-1579.
8. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. 2013. The somatic genomic landscape of glioblastoma. Cell 155:462-477.
9. Brockschmidt A, Trost D, Peterziel H, Zimmermann K, Ehrler M, Grassmann H, Pfenning PN, Waha A, Wohlleber D, Brockschmidt FF, Jugold M, Hoischen A, Kalla C, Waha A, Seifert G, Knolle PA, Latz E, Hans VH, Wick W, Pfeifer A, Angel P, Weber RG. 2012. KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas. Brain 135:1027-1041.
10. Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
11. Cash TP, Gruber JJ, Hartman TR, Henske EP, Simon MC. 2011. Loss of the Birt-Hogg-Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFβ-mediated transcription. Oncogene 30:2534-2546.
12. Chadalapaka G, Jutooru I, Safe S. 2012. Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells. Carcinogenesis 33:886-894.
13. Chelli B, Salvetti A, Da Pozzo E, Rechichi M, Spinetti F, Rossi L, Costa B, Lena A, Rainaldi G, Scatena F, Vanacore R, Gremigni V, Martini C. 2008. PK 11195 differentially affects cell survival in human wild-type and 18 kDa translocator protein-silenced ADF astrocytoma cells. J Cell Biochem 105:712-723.
14. Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O'Connell P, Chang JC. 2006. Gene expression patterns for doxorubicin (adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 95:229-233.
15. Colin C, Voutsinos-Porche B, Nanni I, Fina F, Metellus P, Intagliata D, Baeza N, Bouvier C, Delfino C, Loundou A, Chinot O, Lah T, Kos J, Martin PM, Ouafik L, Figarella-Branger D. 2009. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol 118:745-754.
16. Coupienne I, Fettweis G, Rubio N, Agostinis P, Piette J. 2011. 5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma. Photochem Photobiol Sci 10:1868-1878.
17. Csete B, Lengyel Z, Kádár Z, Battyáni Z. 2009. Poly(adenosine diphosphate-ribose) polymerase-1 expression in cutaneous malignant melanomas as a new molecular marker of aggressive tumor. Pathol Oncol Res 15:47-53.
18. England B, Huang T, Karsy M. 2013. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol 34:2063-2074.
19. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, Durchdewald M, Hess J, Barbus S, Campos B, Starzinski-Powitz A, Unterberg A, Reifenberger G, Lichter P, Herold-Mende C, Radlwimmer B. 2009. Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res 15:6541-6550.
20. Felsberg J, Wolter M, Seul H, Friedensdorf B, Göppert M, Sabel MC, Reifenberger G. 2010. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119:501-507.
21. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Löffler M, Weller M, Reifenberger G, Tonn JC; German Glioma Network. 2011. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129:659-670.
22. Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE, Smith J, Vetrie D, Gorman P, Tomlinson IP, Carter NP. 2003. DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer 36:361-374.
23. Folgueira MA, Carraro DM, Brentani H, Patrão DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, Reis LF, Kaiano JH, Camargo LP, Vêncio RZ, Snitcovsky IM, Makdissi FB, Silva PJ, Góes JC, Brentani MM. 2005. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11:7434-7443.
24. Gardam S, Beyaert R. 2011. The kinase NIK as a therapeutic target in multiple myeloma. Expert Opin Ther Targets 15:207-218.
25. Gilkes D, Bajpai S, Wong CC, Chaturvedi P, Hubbi ME, Wirtz D, Semenza GL. 2013. Procollagen lysyl hydroxylase 2 is essential for breast cancer metastasis. Mol Cancer Res 11:456-466.
26. Guan M, Fousek K, Jiang C, Guo S, Synold T, Xi B, Shih CC, Chow WA. 2011. Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6. Clin Cancer Res 17:1796-1806.
27. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. 2009. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2:ra82.
28. Guo YF, Wang XB, Tian XY, Li Y, Li B, Huang Q, Zhang M, Li Z. 2012. Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro. World J Surg Oncol 10:128.
29. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. 2009. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1, 010 diffuse gliomas. Acta Neuropathol 118:469-474.
30. He L, Yu JX, Liu L, Buyse IM, Wang MS, Yang QC, Nakagawara A, Brodeur GM, Shi YE, Huang S. 1998. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res 58:4238-4244.
31. Hinkle DA, Mullett SJ, Gabris BE, Hamilton RL. 2011. DJ-1 expression in glioblastomas shows positive correlation with p53 expression and negative correlation with epidermal growth factor receptor amplification. Neuropathology 31:29-37.
32. Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Hariono S, Silber J, Feiler HS, Gray JW, Spellman PT, Vandenberg SR, Berger MS, James CD. 2009. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neurol Oncol 11:477-487.
33. Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G; German High-Grade Non-Hodgkin Lymphoma Study Group. 2013. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253-2263.
34. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y. 2009. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15:9-20.
35. Huang Y, Li LZ, Zhang CZ, Yi C, Liu LL, Zhou X, Xie GB, Cai MY, Li Y, Yun JP. 2012. Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosis. J Transl Med 10:106.
36. Huang G, Ho B, Conroy J, Liu S, Qiang H, Golubovskaya V. 2014. The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by Fak Inhibitor Y15 and combination of Y15 and temozolomide. Anticancer Agents Med Chem 14:9-17.
37. Ichimura K, Mungall AJ, Fiegler H, Pearson DM, Dunham I, Carter NP, Collins VP. 2006. Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH. Oncogene 25:1261-1271.
38. Ito M, Wakabayashi T, Natsume A, Hatano H, Fujii M, Yoshida J. 2007. Genetically heterogeneous glioblastoma recurring with disappearance of 1p/19q losses: Case report. Neurosurgery 61:E168-E169.
39. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungall AJ, Jones SJM, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF. 2014. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189-193.
40. Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, St Clair WH. 2006. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 25:1554-1559.
41. Kärrlander M, Lindberg N, Olofsson T, Kastemar M, Olsson AK, Uhrbom L. 2009. Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma. PLoS One 4:e8536.
42. Kleihues P, Burger PC, Aldape K et al. 2007. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavanee WK, editors. WHO Classification of Tumours of the Central Nervous System, 4th ed. Lyon: IARC, pp. 33-49.
43. Koh DW, Dawson TM, Dawson VL. 2005. Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacol Res 52:5-14.
44. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y. 2011. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 30:1956-1962.
45. Kreuz M, Rosolowski M, Berger H, Schwaenen C, Wessendorf S, Loeffler M, Hasenclever D. 2007. Development and implementation of an analysis tool for array-based comparative genomic hybridization. Methods Inform Med 46:608-613.
46. Kühne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmöller J. 2009. Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol 78:45-53.
47. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, Werner M. 2007. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med (Berl) 85:293-304.
48. Lee DW, Ramakrishnan D, Valenta J, Parney IF, Bayless KJ, Sitcheran R. 2013. The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma. PLoS One 8:e57489.
49. Li SC, Vu LT, Ho HW, Yin HZ, Keschrumrus V, Lu Q, Wang J, Zhang H, Ma Z, Stover A, Weiss JH, Schwartz PH, Loudon WG. 2012. Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall. Cancer Cell Int 12:41.
50. Li T, Wang H, Sun Y, Zhao L, Gang Y, Guo X, Huang R, Yang Z, Pan Y, Wu K, Xu L, Liu Z, Fan D. 2013. Transcription factor CUTL1 is a negative regulator of drug resistance in gastric cancer. J Biol Chem 288:4135-4147.
51. Link BC, Reichelt U, Schreiber M, Kaifi JT, Wachowiak R, Bogoevski D, Bubenheim M, Cataldegirmen G, Gawad KA, Issa R, Koops S, Izbicki JR, Yekebas EF. 2007. Prognostic implications of netrin-1 expression and its receptors in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 14:2591-2599.
52. Lourenço SV, Coutinho-Camillo CM, Buim ME, de Carvalho AC, Lessa RC, Pereira CM, Vettore AL, Carvalho AL, Fregnani JH, Kowalski LP, Soares FA. 2010. Claudin-7 down-regulation is an important feature in oral squamous cell carcinoma. Histopathology 57:689-698.
53. Ma J, Cui W, He SM, Duan YH, Heng LJ, Wang L, Gao GD. 2012. Human U87 astrocytoma cell invasion induced by interaction of βig-h3 with integrin α5β1 involves calpain-2. PLoS One 7:e37297.
54. Maeda A, Maeda T, Ohguro H, Palczewski K, Sato N. 2002. Vaccination with recoverin, a cancer-associated retinopathy antigen, induces autoimmune retinal dysfunction and tumor cell regression in mice. Eur J Immunol 32:2300-2307.
55. Martinez R, Rohde V, Schackert G. 2010. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol 96:321-329.
56. Massa A, Barbieri F, Aiello C, Iuliano R, Arena S, Pattarozzi A, Corsaro A, Villa V, Fusco A, Zona G, Spaziante R, Schettini G, Florio T. 2004. The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2. Ann N Y Acad Sci 1030:264-274.
57. McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, Rajaraman P, Razavi P, Patoka J, Wiencke JK, Bondy ML, Wrensch M. 2009. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev 18:1118-1126.
58. Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E, Freitag P, Reubi JC, Müller-Brand J, Gratzl O, Mäcke HR. 1999. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): A pilot study in human gliomas. Clin Cancer Res 5:1025-1033.
59. Nickel GC, Barnholtz-Sloan J, Gould MP, McMahon S, Cohen A, Adams MD, Guda K, Cohen M, Sloan AE, LaFramboise T. 2012. Characterizing mutational heterogeneity in a glioblastoma patient with double recurrence. PLoS One 7:e35262.
60. Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. 2011. The NFκB pathway: A therapeutic target in glioblastoma. Oncotarget 2:646-653.
61. Ohhira M, Fujimoto Y, Matsumoto A, Ohtake T, Ono M, Kohgo Y. 1996. Hepatocellular carcinoma associated with alcoholic liver disease: A clinicopathological study and genetic polymorphism of aldehyde dehydrogenase 2. Alcohol Clin Exp Res 20:378A-382A.
62. Ohtsuka T, Zhou T. 2002. Bisindolylmaleimide VIII enhances DR5-mediated apoptosis through the MKK4/JNK/p38 kinase and the mitochondrial pathways. J Biol Chem 277:29294-29303.
63. Okamura Y, Nomoto S, Kanda M, Hayashi M, Nishikawa Y, Fujii T, Sugimoto H, Takeda S, Nakao A. 2011. Reduced expression of reelin (RELN) gene is associated with high recurrence rate of hepatocellular carcinoma. Ann Surg Oncol 18:572-579.
64. Osawa T, Muramatsu M, Watanabe M, Shibuya M. 2009. Hypoxia and low-nutrition double stress induces aggressiveness in a murine model of melanoma. Cancer Sci 100:844-851.
65. Panicker SP, Raychaudhuri B, Sharma P, Tipps R, Mazumdar T, Mal AK, Palomo JM, Vogelbaum MA, Haque SJ. 2010. p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation. Oncotarget 1:289-303.
66. Papait R, Magrassi L, Rigamonti D, Cattaneo E. 2009. Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells. Biochem Biophys Res Commun 379:434-439.
67. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
68. Peterziel H, Müller J, Danner A, Barbus S, Liu HK, Radlwimmer B, Pietsch T, Lichter P, Schütz G, Hess J, Angel P. 2012. Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. Neuro Oncol 14:426-439.
69. Petty RD, Samuel LM, Murray GI, MacDonald G, O'Kelly T, Loudon M, Binnie N, Aly E, McKinlay A, Wang W, Gilbert F, Semple S, Collie-Duguid ES. 2009. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. BMC Cancer 9:434.
70. Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol O, Beghin A, Valdameri G, Honoré S, Aci-Sèche S, Grierson D, Antonipillai J, Li R, Di Pietro A, Dumontet C, Braguer D, Florent JC, Knapp S, Bernard O, Lafanechère L. 2012. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res 72:4429-4439.
71. Pulvirenti T, Van Der Heijden M, Droms LA, Huse JT, Tabar V, Hall A. 2011. Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res 71:7280-7290.
72. Raif A, Marshall GM, Bell JL, Koach J, Tan O, D'andreti C, Thomas W, Sekyere E, Norris M, Haber M, Kavallaris M, Cheung BB. 2009. The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation. Cancer Lett 277:82-90.
73. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J; HYPOPRONOS. 2010. Prognostic factors in prolactin pituitary tumors: Clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95:1708-1716.
74. Roth W, Wagenknecht B, Klumpp A, Naumann U, Hahne M, Tschopp J, Weller M. 2001. APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis. Cell Death Differ 8:403-410.
75. Roversi G, Pfundt R, Moroni RF, Magnani I, van Reijmersdal S, Pollo B, Straatman H, Larizza L, Schoenmakers EF. 2006. Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene 25:1571-1583.
76. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA Jr, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Hogarty MD. 2013. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 45:12-17.
77. Schraivogel D, Weinmann L, Beier D, Tabatabai G, Eichner A, Zhu JY, Anton M, Sixt M, Weller M, Beier CP, Meister G. 2011. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J 30:4309-4322.
78. Sen GS, Mohanty S, Hossain DM, Bhattacharyya S, Banerjee S, Chakraborty J, Saha S, Ray P, Bhattacharjee P, Mandal D, Bhattacharya A, Chattopadhyay S, Das T, Sa G. 2011. Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem 286:42232-42247.
79. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre JY, Hoang-Xuan K, El Hallani S, Idbaih A, Zelenika D, Andersson U, Henriksson R, Bergenheim AT, Feychting M, Lönn S, Ahlbom A, Schramm J, Linnebank M, Hemminki K, Kumar R, Hepworth SJ, Price A, Armstrong G, Liu Y, Gu X, Yu R, Lau C, Schoemaker M, Muir K, Swerdlow A, Lathrop M, Bondy M, Houlston RS. 2009. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41:899-904.
80. Simpson NE, Lambert WM, Watkins R, Giashuddin S, Huang SJ, Oxelmark E, Arju R, Hochman T, Goldberg JD, Schneider RJ, Reiz LF, Soares FA, Logan SK, Garabedian MJ. 2010. High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance. Cancer Res 70:8446-8456.
81. Sonenshein GE. 1997. Rel/NF-kappa B transcription factors and the control of apoptosis. Semin Cancer Biol 8:113-119.
82. Spiegl-Kreinecker S, Pirker C, Marosi C, Buchroithner J, Pichler J, Silye R, Fischer J, Micksche M, Berger W. 2007. Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. Br J Cancer 96:960-969.
83. Stieber D, Golebiewska A, Evers L, Lenkiewicz E, Brons NH, Nicot N, Oudin A, Bougnaud S, Hertel F, Bjerkvig R, Vallar L, Barrett MT, Niclou SP. 2014. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol 127:203-219.
84. Su X, Chakravarti D, Flores ER. 2013. p63 steps into the limelight: Crucial roles in the suppression of tumorigenesis and metastasis. Nat Rev Cancer 13:136-143.
85. Svojgr K, Kalina T, Kanderova V, Skopcova T, Brdicka T, Zuna J. 2012. The adaptor protein NTAL enhances proximal signaling and potentiates corticosteroid-induced apoptosis in T-ALL. Exp Hematol 40:379-385.
86. Tang Z, Chen WY, Shimada M, Nguyen UT, Kim J, Sun XJ, Sengoku T, McGinty RK, Fernandez JP, Muir TW, Roeder RG. 2013. SET1 and p300 act synergistically, through coupled histone modifications, in transcriptional activation by p53. Cell 154:297-310.
87. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA. 2001. A candidate prostate cancer susceptibility gene at chromosome 17p. Nature Genet 27:172-180.
88. Tesser-Gamba F, Petrilli AS, de Seixas Alves MT, Filho RJ, Juliano Y, Toledo SR. 2012. MAPK7 and MAP2K4 as prognostic markers in osteosarcoma. Hum Pathol 43:994-1002.
89. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F, Sabel MC, Hofmann S, Becker N, Hartmann C, Ohgaki H, von Deimling A, Wiestler OD, Hahn M, Lichter P, Reifenberger G, Radlwimmer B. 2011. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 128:1095-1103.
90. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, Sommer C, Reifenberger G, Hanash SM. 2003. Characterisation of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163:1033-1043.
91. van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, Vandertop PW, Würdinger T, Noske DP, Kaspers GJ, Cloos J. 2011. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2:984-996.
92. Vasseur S, Afzal S, Tardivel-Lacombe J, Park DS, Iovanna JL, Mak TW. 2009. DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc Natl Acad Sci USA 106:1111-1116.
93. Wacker DA, Frizzell KM, Zhang T, Kraus WL. 2007. Regulation of chromatin structure and chromatin-dependent transcription by poly(ADP-ribose) polymerase-1: Possible targets for drug-based therapies. Subcell Biochem 41:45-69.
94. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M. 2009. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J Clin Oncol 27:5743-5750.
95. Weller M, Cloughesy T, Perry JR, Wick W. 2013. Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol 15:4-27.
96. Wu H, Pomeroy SL, Ferreira M, Teider N, Mariani J, Nakayama KI, Hatakeyama S, Tron VA, Saltibus LF, Spyracopoulos L, Leng RP. 2011. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med 17:347-355.
97. Yamaki T, Suenaga Y, Iuchi T, Alagu J, Takatori A, Itami M, Araki A, Ohira M, Inoue M, Kageyama H, Yokoi S, Saeki N, Nakagawara A. 2013. Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma. Sci Rep 3:1160.
98. Yip PY, Kench JG, Rasiah KK, Benito RP, Lee CS, Stricker PD, Henshall SM, Sutherland RL, Horvath LG. 2011. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. Prostate 71:1638-1645.
99. Zage PE, Sirisaengtaksin N, Liu Y, Gireud M, Brown BS, Palla S, Richards KN, Hughes DP, Bean AJ. 2013. UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors. Cancer 119:915-923.
100. Zhao Z, Liu Y, He H, Chen X, Chen J, Lu YC. 2011. Candidate genes influencing sensitivity and resistance of human glioblastoma to Semustine. Brain Res Bull 86:189-194.
101. Zheng S, Chheda MG, Verhaak RG. 2012. Studying a complex tumor: Potential and pitfalls. Cancer J 18:107-114.
102. Zielinski B, Gratias S, Toedt G, Mendrzyk F, Stange DE, Radlwimmer B, Lohmann DR, Lichter P. 2005. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 43:294-301.